P1108 EFFICACY AND TOLERABILITY OF TELAPREVIR-BASED TRIPLE THERAPY FOR ADVANCED FIBROSIS STAGE CHRONIC HEPATITIS C PATIENTS: RESULTS OF THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GROUP

Abstract

response rate. This study aimed to detect types and predictors of interferon induced cardiac complications in Egyptian hepatitis-Cvirus infected patients treated with pegylated interferon/ribavirin combination therapy. Methods: A total of 194, chronic HCV patients were followed up from the time of receiving treatment till one year after end of treatment, to detect cardiac disorders and to determine the response status. Patients were assessed by through history taking, full clinical examination, full laboratory parameters and cardiac assessment using the standard 12 lead ECG and Transthoracic Doppler Echocardiography. Patients in the final analysis were divided into: Group A (who developed cardiac disorders) and group B (who did not develop cardiac disorders). Results: The baseline clinical features (cardiovascular risk factors and hemodynamics) were comparable in both groups. Patients who developed cardiac disorders had higher baseline ALT level, hepatic fibrosis and histologic activity than patients without cardiac disorders (P < 0.05). The confirmed cardiac complications represented 19.6% (n =38) and included left ventricular systolic and diastolic dysfunction, pericardial effusion, arrhythmia, myocardial ischemia and heart failure. Hepatic activity in the liver biopsy, ejection fraction (EF) and left ventricular end diastolic dimension (LVEDD) were independent predictors of the cardiovascular complications. Conclusions: Pegylated interferon therapy of chronic HCV is associated with many types of cardiac complications. Predictors of which are hepatic activity in the liver biopsy, EF and LVEDD in Echocardiography.